# Retatrutide Frequently Asked Questions — Clinic Retatrutide > Retatrutide FAQ: FDA approval status, mechanism, dosage, safety, availability, half-life, and what the Phase 2 and Phase 3 trials report. Direct answers, cited from the research record. Frequently asked questions about Retatrutide, answered directly from the published trial record. Every quantitative claim is cited. For full source detail, see the [clinical trial data](/references) on the references page. See also the [frequently asked questions](/faq) index below. ## What is Retatrutide? Retatrutide (LY3437943) is an investigational once-weekly subcutaneous triple hormone receptor agonist developed by Eli Lilly and Company. It simultaneously activates GLP-1R, GIPR, and GCGR — three distinct receptor families — producing complementary effects on appetite, insulin secretion, and energy expenditure. Phase 2 trials were published in NEJM and the Lancet in 2023 [1][2]. Phase 3 TRIUMPH program results are emerging (2025) [5]. ## How does Retatrutide work? Retatrutide activates three receptor pathways simultaneously. GLP-1R: suppresses appetite, enhances glucose-dependent insulin secretion, slows gastric emptying. GIPR: potentiates insulin secretion, modulates adipose fat metabolism. GCGR: increases brown adipose tissue thermogenesis (via UCP-1 activation), hepatic fatty acid oxidation, and resting energy expenditure — effects that are specifically attributable to the glucagon receptor pathway and that distinguish retatrutide from dual agonists [13]. ## Is Retatrutide FDA Approved? Not as of May 2026. Retatrutide is investigational — no NDA or BLA has been approved by FDA as of this writing. Phase 3 TRIUMPH trials are ongoing. Lilly has not announced commercial availability; accessible only through authorized clinical trial enrollment. Additionally, the compound's regulatory classification (drug/NDA vs. biologic/BLA) was returned to FDA for re-evaluation after a September 2025 court ruling — classification remains unresolved [5]. ## Is Retatrutide safe? Phase 2 data describe a GI-dominant adverse event profile (nausea, vomiting, diarrhea, constipation) consistent with the GLP-1 receptor agonist class. Events were predominantly mild-to-moderate in severity and declined during dose-escalation periods at stable maintenance doses [10]. No major thyroid, pancreatic, or cardiovascular safety signals were identified in Phase 2 human data. Phase 3 long-term safety data are pending [20]. ## What are the risks of taking Retatrutide? Common risks in Phase 2: nausea (up to 60% at 12 mg during titration), diarrhea (15–33%), vomiting (21–26%), constipation (10–20%); higher-dose cohorts had greater GI burden during titration [10]. Mild resting heart rate increase (2–4 bpm) observed [20]. Weight regain after discontinuation is expected based on GLP-1 class biology, with meta-analyses suggesting approximately 75.6% of lost weight may be regained [18]. ## What are the dangers of Retatrutide? Serious adverse events were uncommon in Phase 2; pancreatitis was not elevated above placebo. Class-level concerns include potential thyroid C-cell effects (observed in GLP-1RA rodent models; not detected in Phase 2 human biomarker data) and gallbladder-related events — both under active monitoring in TRIUMPH Phase 3 trials [20]. Dose-dependent GI toxicity at 12 mg drives the highest discontinuation rate (11.3% at 12 mg in TRIUMPH-1) [17]. ## What happens when you stop taking Retatrutide? Based on GLP-1 receptor agonist class biology, weight regain after cessation is expected. A meta-regression of GLP-1RA discontinuation studies found pooled weight regain plateaued at approximately 75.6% of weight lost on treatment [18]. Retatrutide-specific discontinuation data are still emerging from Phase 3 TRIUMPH follow-up extensions. The compound's 6-day half-life means plasma levels clear over approximately 4–5 weeks after the last dose [19]. ## What does Retatrutide do? In Phase 2 clinical trials: 24.2% mean body weight reduction at 48 weeks (12 mg arm, Jastreboff NEJM 2023) [1]; 82.4% liver fat reduction at 24 weeks in MASLD (Sanyal Nature Medicine 2024) [3]; 31.4% android visceral fat reduction by DXA at 36 weeks (Coskun Lancet Diabetes 2025) [6]; -2.02% HbA1c at 36 weeks in T2D [2]; triglycerides -40.6%, non-HDL-C -26.9%, systolic BP up to -11.8 mmHg [11][16]. ## When will Retatrutide be available? Phase 3 TRIUMPH-1 topline results were announced by Eli Lilly in 2025 [5]. An NDA or BLA submission was anticipated in late 2025 pending Phase 3 data readout; FDA review is ongoing. No country has commercially approved retatrutide as of May 2026. Analysts have projected mid-to-late 2026 as a possible approval timeline, pending resolution of regulatory classification and FDA review. ## What is the half-life of Retatrutide? Approximately 6 days in humans, based on Phase 1 pharmacokinetic modeling confirmed across Phase 2 dose groups [19]. The half-life is enabled by a C20 fatty diacid moiety (albumin binding) and Aib2 N-terminal substitution (DPP-4 resistance). Once-weekly subcutaneous dosing was validated across all Phase 2 and Phase 3 trial arms. Steady-state plasma concentrations are reached in approximately 4–5 weeks after initiating treatment. ## How long does Retatrutide take to work? Appetite suppression may emerge within the first 1–2 weeks; measurable body weight reduction typically appears over weeks 4–8 in trial cohorts. The 12 mg arm of the Phase 2 obesity trial showed -12.9% weight at 24 weeks and -24.2% at 48 weeks [1] — indicating ongoing weight loss throughout the 48-week period. Full effect at maintenance dose in Phase 3 TRIUMPH-1 was measured at 80 weeks, yielding -28.3% mean weight at 12 mg [5]. ## Is Retatrutide a GLP-3? Informally, yes — 'GLP-3' is colloquial shorthand for 'triple agonist.' It is not a formal pharmacological classification. 'GLP-3' is not an approved receptor nomenclature in pharmacology; GLP-1 and GLP-2 refer to specific incretin hormones (GLP-2 acts on intestinal epithelium). Retatrutide's precise classification is a GLP-1/GIP/glucagon receptor co-agonist. The informal 'GLP-3' label simply communicates 'one step beyond dual agonism' in patient and lay-press contexts. ## What is the difference between Retatrutide and Tirzepatide? Tirzepatide is a GLP-1/GIP dual agonist; retatrutide adds GCGR activation as a third pathway, producing greater energy expenditure via thermogenesis. A 2024 network meta-analysis in indirect comparison placed retatrutide 12 mg at -22.10% body weight versus -16.53% for the dual agonist at maximum dose [9]. No direct head-to-head randomized trial has been published. Tolerability profiles are similar — both GI-dominant. Mechanistically, the glucagon receptor component of retatrutide drives additional thermogenic and hepatic-fat effects. ## How to reconstitute Retatrutide? For lyophilized research-grade peptide: inject bacteriostatic water slowly against the vial wall (not directly onto powder), swirl gently — do not shake. Standard ratio: 1 mL bacteriostatic water per mg peptide yields 1 mg/mL. Inspect for clarity before use. Lilly's clinical trial formulation was not reconstituted by participants — supplied as pre-formulated solution in an autoinjector pen. Research-grade lyophilized peptides are not FDA-reviewed for safety or sterility. ## How to store Retatrutide? Lyophilized powder: stable at -20°C long-term; avoid repeated freeze-thaw cycles. Reconstituted solution: store at 2–8°C (refrigerator) and use within 28–30 days. Do not freeze reconstituted solution. Protect from light. These guidelines reflect standard peptide-handling protocols documented in research literature, not FDA-approved labeling — retatrutide has no approved labeling as of May 2026. ## Is Retatrutide legal? Retatrutide is not scheduled as a controlled substance. It is an investigational drug regulated under FDA IND provisions. Research-grade retatrutide peptides are sold by peptide suppliers under research-use-only designations, not approved for human therapeutic use outside authorized clinical trial enrollment. WADA's Prohibited List includes non-approved pharmacological substances under Section S0; athletes should consult WADA guidance directly. ## What company makes Retatrutide? Eli Lilly and Company developed retatrutide (LY3437943) as part of their GLP-based metabolic drug pipeline. All registered trials are Lilly-sponsored. Trial registrations appear on ClinicalTrials.gov under NCT04881760 (Phase 2 obesity), NCT04867785 (Phase 2 T2D), NCT05651776 (TRIUMPH-1 Phase 3), and related identifiers. ## What is Retatrutide used for? Primary research indication: chronic weight management in adults with obesity. Secondary indications under active Phase 3 investigation: type 2 diabetes glycemic control, metabolic dysfunction-associated steatotic liver disease (MASLD), knee osteoarthritis pain reduction via weight loss (TRIUMPH-4 data published 2025) [8], obstructive sleep apnea, and cardiovascular risk factor reduction (TRIUMPH-3 ongoing). No indication is approved as of May 2026. ## Do Retatrutide side effects happen right away? GI side effects (nausea, vomiting) in Phase 2 trials were most frequent during initial dose escalation (weeks 1–8); onset for some participants occurred within hours of the first injection [10]. Events typically attenuated with continued use at stable maintenance doses. The highest-dose (12 mg) arm had the greatest GI burden during titration — but also the greatest weight reduction at maintenance. ## What to Expect During Retatrutide Treatment Phase 2 trial data suggest: appetite reduction may be felt within the first 1–2 weeks; GI discomfort (nausea, constipation, vomiting) peaks during dose escalation (weeks 1–8); measurable body weight reduction typically emerges over weeks 4–8; energy and satiety signaling changes are commonly reported in trial participant accounts. Full Phase 2 effect was measured at 24 and 48 weeks [1]; Phase 3 TRIUMPH-1 primary endpoint is at 80 weeks [5]. ## Does Retatrutide target belly fat? Phase 2 DXA imaging showed preferential android visceral adipose tissue (VAT) reduction — up to 31.4% at 36 weeks in the 8 mg T2D arm (Coskun 2025, Lancet Diabetes and Endocrinology) [6]. The glucagon receptor component is thought to drive hepatic fat and visceral fat mobilization via cAMP-mediated lipolysis beyond what GLP-1R agonism alone achieves. MRI-PDFF confirmed 82.4% relative liver fat reduction at 24 weeks in the MASLD Phase 2a study [3]. ## Is Retatrutide better than Tirzepatide? Indirect comparison of Phase 2/3 data suggests greater mean percent weight loss at comparable time points: retatrutide 12 mg at -22.10% body weight versus the dual agonist at maximum dose at -16.53% (network meta-analysis, PubMed 2024) [9]. No head-to-head randomized trial exists as of mid-2026; TRIUMPH-5 is planned for direct comparison. Tolerability profiles are similar. Mechanistic differences favor retatrutide for thermogenic effect via the glucagon receptor pathway. ## Retatrutide Availability in the United States Not commercially available as of May 2026. Accessible only through Lilly-sponsored clinical trial enrollment. Phase 3 TRIUMPH-1 topline results were announced in 2025 [5]; FDA NDA or BLA review is ongoing following Phase 3 data submission. No country has commercially approved retatrutide. Research-grade retatrutide peptides are sold by vendors under research-use-only designations, without FDA safety or efficacy review. ## What is the Retatrutide dosage schedule? Phase 3 TRIUMPH protocol initiates at 2.5 mg once weekly (weeks 1–4), escalating in 2.5 mg increments every 4 weeks to a target maintenance dose of 12 mg per week [5]. Phase 2 trials used similar graduated titration starting at 2 mg. Slower titration is the primary strategy for managing GI adverse events during the escalation period [10]. Dosing is subcutaneous, once weekly. ## How much Retatrutide per week? Phase 2 studied 0.5, 1, 4, 8, and 12 mg once weekly subcutaneous. Maximum studied dose: 12 mg per week. Phase 3 TRIUMPH-1 arms: 4 mg, 9 mg, 12 mg. No dose above 12 mg per week has been reported in published trials. Once-weekly administration is supported by the compound's approximately 6-day plasma half-life [19]. ## Expected Retatrutide Approval and Launch Timeline Phase 3 TRIUMPH-1 topline results and TRIUMPH-4 results were announced in 2025 [5][8]. An NDA or BLA submission in late 2025 was anticipated following Phase 3 readout. FDA decision is expected in 2026; Eli Lilly has not announced a commercial launch date. The BLA vs. NDA classification dispute (returned to FDA for re-evaluation after September 2025 court ruling) adds regulatory uncertainty to the timeline. ## Retatrutide Regulatory Status Outside the USA No country has commercially approved retatrutide as of May 2026. The European Medicines Agency (EMA) and other regulatory bodies have not granted authorization. Eli Lilly has filed regulatory submissions in select markets, but no approvals had been announced as of this writing. The compound remains investigational globally. --- A peer-reviewed reading desk — not a clinic, not a vendor, not a source of medical guidance.